Academia, CAR-T, Collaborations

Atara brings another experienced investigator onto its off-the-shelf CAR-T quest in latest collaboration

An ambitious Atara has signed up another cancer research center to beef up its pipeline of off-the-shelf CAR-T therapies.

In the new collaboration, the Amgen spinoff $ATRA will “contribute resources and relevant experience to the research activities” at Moffitt Cancer Center in Tampa, FL. They will work closely with Marco Davila, a veteran researcher in the field who trained with top CAR-T investigator Michel Sadelain at Memorial Sloan Kettering.

Marco Davila

Both of the CAR-T therapies currently on the market — Novartis’ Kymriah and Gilead’s Yescarta — target a single antigen called CD19. Like some other groups pursuing next-gen CAR-T drugs, Atara is hoping to engineer the T cells in a way that can tackle multiple targets, thereby addressing cancers with diverse cell types that often become resistant to treatment, such as acute myelogenous leukemia and B cell malignancies.

The partners will also look into novel co-stimulatory domains based on CD28 and 4-1BB, which are meant to improve the modified T cells’ anti-cancer activity.

Dietmar Berger

By combining Atara’s Epstein-Barr virus-specific “T-cell platform, development, manufacturing and regulatory expertise with cutting edge T-cell engineering discoveries by our external collaborators,” says R&D chief Dietmar Berger, this pact will build their preclinical CAR-T pipeline, which is currently supported by an extensive collaboration with MSK.

Berger, a Genentech vet, was brought in a few months ago to steer Atara’s allogeneic T cell immunotherapies through the clinic, both in CAR-T and other applications.

Atara’s most advanced program, tabelecleucel, or tab-cel, is being developed for patients with EBV-associated post-transplant lymphoproliferative disorder, as well as other EBV-associated hematologic and solid tumors, including nasopharyngeal carcinoma).

“Atara is a leader in the development of off-the-shelf, allogeneic T-cell immunotherapies based on their novel EBV-specific T-cell technology platform,” said Davila in a statement. “I look forward to rapidly advancing our CAR T engineering and multi-antigen targeting technologies with Atara to address the high unmet need in patients with advanced AML and B-cell malignancies.”

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->